Industrial-scale manufacturing of Cinryze (C1-esterase inhibitor, human) will stay on schedule despite an FDA complete response letter requesting additional information about the expansion, according to ViroPharma Inc.'s President and CEO Vincent Milano. (BioWorld Today) Read More
